東華大學圖書館 |

Anticancer drug development

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Anticancer drug development/ edited by Bruce C. Baguley, David J. Kerr.{me_controlnum}
其他作者:	Baguley, Bruce C.
出版者:	San Diego :Academic Press, : c2002.,
面頁冊數:	1 online resource (xiii, 397 p.) :ill. (some col.)
內容註:	A brief history of cancer chemotherapy -- Novel targets in the cell cycle and cell cycle checkpoints -- Growth factor and signal transduction targets for cancer therapy -- Cell death pathways as targets for anticancer drugs -- Drug resistance pathways as targets -- Role of matrix metalloproteinases and plasminogen activators in cancer invasion and metastasis: therapeutic strategies -- Tumor vasculature as a target -- Gene-directed enzyme prodrug therapy -- Tumor antigens as targets for anticancer drug development -- Structure-based drug design and its contributions to cancer chemotherapy -- The contribution of synthetic organic chemistry to anticancer drug development -- Biosynthetic products for anticancer drug design and treatment: the bryostatins -- DNA-encoded peptide libraries and drug discovery -- Mechanism-based high-throughput screening for novel anticancer drug discovery -- Tumor cell cultures in drug development -- Screening using animal systems -- Relevance of preclinical pharmacology and toxicology to Phase I trial extrapolation techniques: relevance of animal toxicity -- Clinical trial design: incorporation of pharmacokinetic, pharmacodynamic, and pharmacogenetic principle -- Tumor imaging applications in the testing of new drugs -- Mechanistic approaches to Phase I clinical trials.
標題:	Antineoplastic agents. -
電子資源:	http://www.sciencedirect.com/science/book/9780120726516
ISBN:	9780120726516

Anticancer drug development
Anticancer drug development[electronic resource] /edited by Bruce C. Baguley, David J. Kerr.{me_controlnum} - San Diego :Academic Press,c2002. - 1 online resource (xiii, 397 p.) :ill. (some col.)

Includes bibliographical references and index.

A brief history of cancer chemotherapy -- Novel targets in the cell cycle and cell cycle checkpoints -- Growth factor and signal transduction targets for cancer therapy -- Cell death pathways as targets for anticancer drugs -- Drug resistance pathways as targets -- Role of matrix metalloproteinases and plasminogen activators in cancer invasion and metastasis: therapeutic strategies -- Tumor vasculature as a target -- Gene-directed enzyme prodrug therapy -- Tumor antigens as targets for anticancer drug development -- Structure-based drug design and its contributions to cancer chemotherapy -- The contribution of synthetic organic chemistry to anticancer drug development -- Biosynthetic products for anticancer drug design and treatment: the bryostatins -- DNA-encoded peptide libraries and drug discovery -- Mechanism-based high-throughput screening for novel anticancer drug discovery -- Tumor cell cultures in drug development -- Screening using animal systems -- Relevance of preclinical pharmacology and toxicology to Phase I trial extrapolation techniques: relevance of animal toxicity -- Clinical trial design: incorporation of pharmacokinetic, pharmacodynamic, and pharmacogenetic principle -- Tumor imaging applications in the testing of new drugs -- Mechanistic approaches to Phase I clinical trials.

Here in a single source is a complete spectrum of ideas on the development of new anticancer drugs. Containing concise reviews of multidisciplinary fields of research, this book offers a wealth of ideas on current and future molecular targets for drug design, including signal transduction, the cell division cycle, and programmed cell death. Detailed descriptions of sources for new drugs and methods for testing and clinical trial design are also provided. KEY FEATURES: * One work that can be consulted for all aspects of anticancer drug development * Concise reviews of research fields, combined with practical scientific detail, written by internationally respected experts * A wealth of ideas on current and future molecular targets for drug design, including signal transduction, the cell division cycle, and programmed cell death * Detailed descriptions of the sources of new anticancer drugs, including combinatorial chemistry, phage display, and natural products * Discussion of how new drugs can be tested in preclinical systems, including the latest technology of robotic assay systems, cell culture, and experimental animal techniques * Hundreds of references that allow the reader to access relevant scientific and medical literature * Clear illustrations, some in color, that provide both understanding of the field and material for teaching.

ISBN: 9780120726516

Source: 88755:88755Elsevier Science & Technologyhttp://www.sciencedirect.comSubjects--Topical Terms:

795427
Antineoplastic agents.
Index Terms--Genre/Form:

542853
Electronic books.

LC Class. No.: RS431.A64 / A564 2002eb

Dewey Class. No.: 616.99/4061

National Library of Medicine Call No.: 2002 B-638

Anticancer drug development
LDR:04297cmm 2200421Ia 4500 001 1325802
005 20120813074840.0
006 m d
007 cr cn|||||||||
008 130122s2002 caua ob 001 0 eng d
019 $a 154725073 $a 648303302 $a 779916060
020 $a 9780120726516
020 $a 0120726513
020 $a 9780080490441 (electronic bk.)
020 $a 0080490441 (electronic bk.)
029 1 $a NZ1 $b 12434043
029 1 $a AU@ $b 000048129579
029 1 $a DEBBG $b BV039829030
035 $a ocn162129299
037 $a 88755:88755 $b Elsevier Science & Technology $n http://www.sciencedirect.com
040 $a OPELS $b eng $c OPELS $d OCLCQ $d N$T $d YDXCP $d IDEBK $d E7B $d OCLCQ $d TULIB $d OCLCO
049 $a NTYA
050 4 $a RS431.A64 $b A564 2002eb
060 4 $a 2002 B-638
060 4 $a QV 269 $b A629515 2002
072 7 $a MED $x 062000 $2 bisacsh
072 7 $a HEA $x 039030 $2 bisacsh
082 0 4 $a 616.99/4061 $2 22
245 0 0 $a Anticancer drug development $h [electronic resource] / $c edited by Bruce C. Baguley, David J. Kerr.{me_controlnum}
260 $a San Diego : $b Academic Press, $c c2002.
300 $a 1 online resource (xiii, 397 p.) : $b ill. (some col.)
504 $a Includes bibliographical references and index.
505 0 $a A brief history of cancer chemotherapy -- Novel targets in the cell cycle and cell cycle checkpoints -- Growth factor and signal transduction targets for cancer therapy -- Cell death pathways as targets for anticancer drugs -- Drug resistance pathways as targets -- Role of matrix metalloproteinases and plasminogen activators in cancer invasion and metastasis: therapeutic strategies -- Tumor vasculature as a target -- Gene-directed enzyme prodrug therapy -- Tumor antigens as targets for anticancer drug development -- Structure-based drug design and its contributions to cancer chemotherapy -- The contribution of synthetic organic chemistry to anticancer drug development -- Biosynthetic products for anticancer drug design and treatment: the bryostatins -- DNA-encoded peptide libraries and drug discovery -- Mechanism-based high-throughput screening for novel anticancer drug discovery -- Tumor cell cultures in drug development -- Screening using animal systems -- Relevance of preclinical pharmacology and toxicology to Phase I trial extrapolation techniques: relevance of animal toxicity -- Clinical trial design: incorporation of pharmacokinetic, pharmacodynamic, and pharmacogenetic principle -- Tumor imaging applications in the testing of new drugs -- Mechanistic approaches to Phase I clinical trials.
520 $a Here in a single source is a complete spectrum of ideas on the development of new anticancer drugs. Containing concise reviews of multidisciplinary fields of research, this book offers a wealth of ideas on current and future molecular targets for drug design, including signal transduction, the cell division cycle, and programmed cell death. Detailed descriptions of sources for new drugs and methods for testing and clinical trial design are also provided. KEY FEATURES: * One work that can be consulted for all aspects of anticancer drug development * Concise reviews of research fields, combined with practical scientific detail, written by internationally respected experts * A wealth of ideas on current and future molecular targets for drug design, including signal transduction, the cell division cycle, and programmed cell death * Detailed descriptions of the sources of new anticancer drugs, including combinatorial chemistry, phage display, and natural products * Discussion of how new drugs can be tested in preclinical systems, including the latest technology of robotic assay systems, cell culture, and experimental animal techniques * Hundreds of references that allow the reader to access relevant scientific and medical literature * Clear illustrations, some in color, that provide both understanding of the field and material for teaching.
588 $a Description based on print version record.
650 0 $a Antineoplastic agents. $3 795427
650 0 $a Drug development. $3 716904
650 1 2 $a Antineoplastic Agents. $3 826993
650 2 2 $a Drug Design. $3 550958
650 2 2 $a Drug Evaluation, Preclinical. $3 752567
650 6 $a Anticanc�ereux $x D�eveloppement. $3 1614022
650 6 $a Cancer $x Chimioth�erapie. $3 1614023
650 7 $a MEDICAL $x Oncology. $2 bisacsh $3 1614024
650 7 $a HEALTH & FITNESS $x Diseases $x Cancer. $2 bisacsh $3 1614025
655 4 $a Electronic books. $2 lcsh $3 542853
700 1 $a Baguley, Bruce C. $3 1614020
700 1 $a Kerr, David J. $3 1614021
776 0 8 $i Print version: $t Anticancer drug development. $d San Diego : Academic Press, c2002 $z 0120726513 $z 9780120726516 $w (DLC) 2001090931 $w (OCoLC)47901452
856 4 0 $3 ScienceDirect $u http://www.sciencedirect.com/science/book/9780120726516
938 $a YBP Library Services $b YANK $n 2599488
938 $a ebrary $b EBRY $n ebr10186392